Exact Sciences (EXAS) – Research Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Exact Sciences (NASDAQ: EXAS):

• 11/11/2024 – Exact Sciences had its price target lowered by analysts at Piper Sandler from $85.00 to $75.00. They now have an “overweight” rating on the stock.
• 11/6/2024 – Exact Sciences had its price target lowered by analysts at Evercore ISI from $80.00 to $60.00. They now have an “outperform” rating on the stock.
• 11/6/2024 – Exact Sciences had its price target lowered by analysts at Robert W. Baird from $70.00 to $67.00. They now have an “outperform” rating on the stock.
• 11/6/2024 – Exact Sciences had its price target raised by analysts at Jefferies Financial Group Inc. from $84.00 to $85.00. They now have a “buy” rating on the stock.
• 11/6/2024 – Exact Sciences had its price target lowered by analysts at Citigroup Inc. from $80.00 to $75.00. They now have a “buy” rating on the stock.
• 11/6/2024 – Exact Sciences had its price target lowered by analysts at Canaccord Genuity Group Inc. from $95.00 to $75.00. They now have a “buy” rating on the stock.
• 11/6/2024 – Exact Sciences had its price target lowered by analysts at Stifel Nicolaus from $82.00 to $67.00. They now have a “buy” rating on the stock.
• 11/6/2024 – Exact Sciences had its price target lowered by analysts at BTIG Research from $82.00 to $65.00. They now have a “buy” rating on the stock.
• 11/6/2024 – Exact Sciences had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $75.00 to $65.00. They now have a “buy” rating on the stock.
• 11/6/2024 – Exact Sciences had its price target lowered by analysts at TD Cowen from $90.00 to $82.00. They now have a “buy” rating on the stock.
• 11/6/2024 – Exact Sciences had its price target lowered by analysts at Benchmark Co. from $67.00 to $65.00. They now have a “buy” rating on the stock.
• 11/6/2024 – Exact Sciences had its price target lowered by analysts at Craig Hallum from $82.00 to $65.00. They now have a “buy” rating on the stock.
• 10/30/2024 – Exact Sciences had its price target raised by analysts at Sanford C. Bernstein from $75.00 to $90.00. They now have an “outperform” rating on the stock.
• 10/29/2024 – Exact Sciences had its price target raised by analysts at Canaccord Genuity Group Inc. from $75.00 to $95.00. They now have a “buy” rating on the stock.
• 10/1/2024 – Exact Sciences had its price target raised by analysts at Evercore ISI from $72.00 to $80.00. They now have an “outperform” rating on the stock.
• 9/26/2024 – Exact Sciences had its “market perform” rating reaffirmed by analysts at Raymond James.

Exact Sciences Price Performance

Shares of EXAS stock opened at $50.73 on Thursday. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $79.62. The company has a current ratio of 2.12, a quick ratio of 1.93 and a debt-to-equity ratio of 0.72. The firm’s 50 day moving average is $66.22 and its 200-day moving average is $56.30. The firm has a market capitalization of $9.39 billion, a price-to-earnings ratio of -43.36 and a beta of 1.27.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $708.66 million for the quarter, compared to analyst estimates of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. The firm’s revenue for the quarter was up 12.8% on a year-over-year basis. Sell-side analysts forecast that Exact Sciences Co. will post -1.08 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Brian Baranick sold 929 shares of the stock in a transaction that occurred on Tuesday, October 8th. The shares were sold at an average price of $70.00, for a total value of $65,030.00. Following the transaction, the executive vice president now directly owns 12,758 shares in the company, valued at $893,060. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, EVP Brian Baranick sold 929 shares of the company’s stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the completion of the sale, the executive vice president now owns 12,758 shares in the company, valued at approximately $893,060. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Kevin T. Conroy bought 19,500 shares of Exact Sciences stock in a transaction on Wednesday, November 13th. The shares were bought at an average price of $51.35 per share, for a total transaction of $1,001,325.00. Following the acquisition, the chief executive officer now owns 1,074,191 shares of the company’s stock, valued at approximately $55,159,707.85. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.36% of the company’s stock.

Institutional Investors Weigh In On Exact Sciences

Several large investors have recently bought and sold shares of the company. RPg Family Wealth Advisory LLC acquired a new position in shares of Exact Sciences in the 3rd quarter valued at $34,000. Soros Capital Management LLC acquired a new position in Exact Sciences in the third quarter valued at about $3,522,000. The Manufacturers Life Insurance Company grew its stake in Exact Sciences by 35.7% in the third quarter. The Manufacturers Life Insurance Company now owns 136,592 shares of the medical research company’s stock valued at $9,305,000 after acquiring an additional 35,927 shares during the period. Daiwa Securities Group Inc. raised its position in shares of Exact Sciences by 12.8% during the third quarter. Daiwa Securities Group Inc. now owns 14,147 shares of the medical research company’s stock worth $964,000 after purchasing an additional 1,600 shares during the period. Finally, Cerity Partners LLC raised its position in shares of Exact Sciences by 193.8% during the third quarter. Cerity Partners LLC now owns 16,329 shares of the medical research company’s stock worth $1,112,000 after purchasing an additional 10,772 shares during the period. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.